Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.56 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482075 | 1.00 | PTGS1 (0.56) | PTGS1PTGS2LMNAMAPTCXCR1 | |
| SCHEMBL1882145 | 0.88 | CXCL8 (0.48) | LMNAMAPTSMN1; SMN2CXCL8ALDH1A1 | |
| SCHEMBL1884898 | 0.81 | TYK2 (0.47) | LMNAMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1437928 | 0.77 | KMT2A (0.80) | LMNAMAPTSMN1; SMN2HPGDKMT2A | |
| SCHEMBL6717009 | 0.74 | PTGS1 (0.72) | PTGS1PTGS2LMNAMAPTCXCR1 | |
| SCHEMBL1344993 | 0.74 | PTGS1 (0.72) | PTGS1PTGS2LMNAMAPTCXCR1 | |
| SCHEMBL1344992 | 0.74 | PTGS1 (0.72) | PTGS1PTGS2LMNAMAPTCXCR1 | |
| SCHEMBL602096 | 0.73 | PTGS2 (0.69) | PTGS1PTGS2LMNAMAPTCXCR1 | |
| SCHEMBL5311714 | 0.72 | PTGS2 (0.79) | PTGS1PTGS2LMNAMAPTCXCR1 | |
| Ketoprofen SCHEMBL3843886 | 0.72 | PTGS1 (1.00) | PTGS1PTGS2LMNAMAPTCXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939521-B2 | 2-arylpropionic acid derivatives and pharmaceutical compositions containing them | DompePHA.R.MA S.p.A. (IT) | 2011-05-10 | — | — | US | disclosed |
| EP-1856031-B1 | 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-02-25 | — | — | EP | disclosed |
| US-20080312293-A1 | 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them | DOMPE' PHA.R.MA.S.P.A. (IT) | 2008-12-18 | — | — | US | disclosed |
| EP-1856031-A1 | 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006063999-A1 | 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA.S.P.A. (IT) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312293-A1 | 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them | C3AR1, C5AR2, C5AR1 | PTGS1 197/4885PTGS2 137/4885LMNA 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.